Financial Performance Summary

Quarterly Performance (Q2 FY27 vs Q2 FY26):

  • Revenue from Operations: ₹8,741.61 lakhs (vs ₹5,756.04 lakhs) - 53% YoY growth
  • Gross Profit: ₹4,168.05 lakhs (vs ₹2,715.40 lakhs) - 53% YoY growth
  • Gross Profit Margin: 48% (vs 47%)
  • EBITDA: ₹2,434.53 lakhs (vs ₹1,135.39 lakhs) - 114% YoY growth
  • EBITDA Margin: 28% (vs 20%)
  • Profit After Tax: ₹1,130.69 lakhs (vs ₹453.98 lakhs) - 149% YoY growth
  • PAT Margin: 13% (vs 8%)

Half-Yearly Performance (H1 FY27 vs H1 FY26):

  • Revenue from Operations: ₹16,038.86 lakhs (vs ₹11,029.66 lakhs)
  • Gross Profit: ₹8,007.08 lakhs (vs ₹5,093.78 lakhs) - 57% YoY growth
  • Gross Profit Margin: 50% (vs 46%)
  • EBITDA: ₹4,559.42 lakhs (vs ₹2,405.97 lakhs) - 90% YoY growth
  • EBITDA Margin: 28% (vs 22%)
  • Profit After Tax: ₹2,159.18 lakhs (vs ₹921.11 lakhs) - 134% YoY growth
  • PAT Margin: 13% (vs 8%)

Business Highlights and Operational Metrics

Regulatory and Commercial Progress:

  • Executed 69 oncology product contracts with 45 commercial discussions underway
  • Shared 351 dossiers globally, with 191 submitted to regulatory agencies
  • 22 Marketing Authorizations (MAs) granted globally:
  • Europe & UK: 11 MAs
  • Latin America: 6 MAs
  • APAC: 4 MAs
  • Canada: 1 MA
  • Completed 36 EU MA applications including 16 own filings
  • Submitted 33 site variations covering 18 cytotoxic molecules
  • 11 site variation approvals received in stringent markets of EU and UK

Technology and Development:

  • 33 technology transfer projects for oncology products underway with 4 partners
  • Developed 21 APIs in-house including:
  • 16 APIs with Written Confirmation
  • 8 commercialized products
  • 2 of 7 CEP applications approved with 5 in process

Facility and Supply Chain:

  • Commercial supplies commenced from API-integrated, EU GMP-approved oncology FDF site
  • Accord received 6 more product site variations approval by EMA (total now 8 of 11 molecules)
  • 3 additional site variation approvals from MHRA/EMA for partners in UK and Germany

Product Portfolio:

  • Coverage expanded to cancers of breast, lung, prostate, stomach, head & neck, colorectal, ovary, liver, kidney, thyroid, blood, bone-marrow and lymph

Management Commentary

Mr. Sanjay Shah, Managing Director, commented:

  • Q2 FY27 represented meaningful progress for oncology business with encouraging developments across regulatory approvals, technology transfers and global market access
  • Commencement of commercial supplies from EU GMP-approved, API-integrated oncology facility marks an important milestone
  • In-house API capabilities and ongoing technology transfers are strengthening the integrated platform
  • Enhanced supply-chain control and expanded ability to serve regulated markets
  • Optimistic about opportunities from expanding oncology portfolio, growing pipeline and international partnerships
  • Expects these developments to support export growth, improved capacity utilization and operating efficiencies
  • Positions company for sustainable, long-term growth

Company Background

Sakar Healthcare Limited, established in 2004 and headquartered in Ahmedabad, Gujarat, is a publicly listed pharmaceutical manufacturer and exporter specializing in:

  • Oncology
  • Antibiotics
  • General formulations

Operates world-class, EU-GMP and WHO-GMP certified facilities manufacturing:

  • Oral solids
  • Injectables
  • Oral liquids
  • High-potent oncology products

Oncology division at Bavla represents research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs

Global footprint across more than 60 countries serving multinational pharmaceutical companies through:

  • CDMO collaborations
  • CRAMS partnerships
  • Technology transfer collaborations

Driven by vision to deliver world-class healthcare solutions with strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles.